

# European Respiratory Society Annual Congress 2013

**Abstract Number:** 5499

**Publication Number:** 4650

**Abstract Group:** 10.1. Respiratory Infections

**Keyword 1:** Bronchiectasis **Keyword 2:** Bacteria **Keyword 3:** Monitoring

**Title:** Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis

Dr. Charles 30525 Haworth charles.haworth@papworth.nhs.uk MD <sup>1</sup>, Dr. Diana 30536 Bilton D.Bilton@rbht.nhs.uk MD <sup>2</sup> and Dr. Robert 30537 Kenyon robert.kenyon@profilepharma.com <sup>3</sup>. <sup>1</sup> Thoracic Medicine, Papworth Hospital, Cambridge, United Kingdom ; <sup>2</sup> Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom and <sup>3</sup> Research, Profile Pharma Ltd, Chichester, United Kingdom .

**Body:** Adherence to inhaled medication treatment regimens is typically poor. <sup>[1]</sup> The I-neb AAD System is used by patients with cystic fibrosis (CF) for the aerosolised delivery of precise doses of colistimethate sodium (CMS; Promixin, Profile Pharma Ltd) and features routine recording of adherence data. We report on the adherence of patients enrolled in a pioneer, 6 month, multinational, double-blind, placebo-controlled study of the delivery of CMS via the I-neb AAD System to patients with non-CF bronchiectasis colonised by *Pseudomonas aeruginosa* [ISRCTN49790596]. Patients (n=144) were enrolled and randomised to twice daily CMS (1 MIU/mL) or placebo (0.45% saline), delivered using the I-neb AAD System (Table 1). Adherence data was examined at the end of the study.

Table 1. Patient demographics.

Randomisation arm	CMS	Placebo
Number (n)	73	71
Males (n)	27	34
Caucasian (n)	72	71
Median age in years (range)	62 (18 to 84)	63 (18 to 90)
Completed study (n)	62	60

Adherence exhibited by patients in both arms of the study was very high; 75% of patients demonstrated mean adherence of over 80% to their prescribed doses, and mean overall study adherence was 86%. This compares favourably with median nebuliser adherence of 36% in adult patients with CF. <sup>[1]</sup> 1. Daniels T et

al. Chest 2011;140:425-432.